JP2021503888A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021503888A5 JP2021503888A5 JP2020526382A JP2020526382A JP2021503888A5 JP 2021503888 A5 JP2021503888 A5 JP 2021503888A5 JP 2020526382 A JP2020526382 A JP 2020526382A JP 2020526382 A JP2020526382 A JP 2020526382A JP 2021503888 A5 JP2021503888 A5 JP 2021503888A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antibody
- seq
- acid sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 138
- 150000001413 amino acids Chemical group 0.000 claims description 136
- 239000000427 antigen Substances 0.000 claims description 117
- 102000036639 antigens Human genes 0.000 claims description 117
- 108091007433 antigens Proteins 0.000 claims description 117
- 210000004027 cell Anatomy 0.000 claims description 66
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 claims description 49
- 101710082516 C-X-C chemokine receptor type 5 Proteins 0.000 claims description 49
- 150000007523 nucleic acids Chemical class 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 125000000539 amino acid group Chemical group 0.000 claims description 24
- 108020004707 nucleic acids Proteins 0.000 claims description 23
- 102000039446 nucleic acids Human genes 0.000 claims description 23
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 22
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 20
- 235000003704 aspartic acid Nutrition 0.000 claims description 20
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 20
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 20
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 16
- 210000005259 peripheral blood Anatomy 0.000 claims description 16
- 239000011886 peripheral blood Substances 0.000 claims description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 208000026278 immune system disease Diseases 0.000 claims description 15
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 14
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 claims description 12
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 208000011580 syndromic disease Diseases 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 10
- 201000004624 Dermatitis Diseases 0.000 claims description 9
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 8
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 8
- 239000004473 Threonine Substances 0.000 claims description 8
- 235000004279 alanine Nutrition 0.000 claims description 8
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 8
- 239000013612 plasmid Substances 0.000 claims description 8
- 210000000952 spleen Anatomy 0.000 claims description 8
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 6
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 claims description 6
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 claims description 6
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 6
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 6
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 claims description 6
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 claims description 6
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 6
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 claims description 6
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 6
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 6
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 6
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 claims description 6
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 claims description 6
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 claims description 6
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims description 6
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims description 6
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 6
- 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 claims description 6
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims description 6
- -1 CXCR3R1 Proteins 0.000 claims description 6
- 102100031011 Chemerin-like receptor 1 Human genes 0.000 claims description 6
- 101000777558 Homo sapiens C-C chemokine receptor type 10 Proteins 0.000 claims description 6
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims description 6
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 6
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 claims description 6
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 claims description 6
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 claims description 6
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims description 6
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 6
- 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 claims description 6
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims description 6
- 101000919756 Homo sapiens Chemerin-like receptor 1 Proteins 0.000 claims description 6
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims description 6
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 6
- 230000001363 autoimmune Effects 0.000 claims description 6
- 230000000779 depleting effect Effects 0.000 claims description 6
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims description 4
- 102100035294 Chemokine XC receptor 1 Human genes 0.000 claims description 4
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 4
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 claims description 4
- 101000804783 Homo sapiens Chemokine XC receptor 1 Proteins 0.000 claims description 4
- 208000028622 Immune thrombocytopenia Diseases 0.000 claims description 4
- 241000282567 Macaca fascicularis Species 0.000 claims description 4
- 101100497636 Mus musculus Cxcr5 gene Proteins 0.000 claims description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
- 208000007502 anemia Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 230000004071 biological effect Effects 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 230000003325 follicular Effects 0.000 claims description 4
- 102000049118 human CXCR5 Human genes 0.000 claims description 4
- 230000006054 immunological memory Effects 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 206010028372 Muscular weakness Diseases 0.000 claims description 3
- 230000036473 myasthenia Effects 0.000 claims description 3
- 206010027654 Allergic conditions Diseases 0.000 claims description 2
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 claims description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims description 2
- 208000004736 B-Cell Leukemia Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 208000006313 Delayed Hypersensitivity Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 2
- 208000031220 Hemophilia Diseases 0.000 claims description 2
- 208000009292 Hemophilia A Diseases 0.000 claims description 2
- 101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 claims description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 2
- 206010021263 IgA nephropathy Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010029240 Neuritis Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000033464 Reiter syndrome Diseases 0.000 claims description 2
- 206010038910 Retinitis Diseases 0.000 claims description 2
- 206010040968 SLE arthritis Diseases 0.000 claims description 2
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 241000519995 Stachys sylvatica Species 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 208000000389 T-cell leukemia Diseases 0.000 claims description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 231100000360 alopecia Toxicity 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 230000012085 chronic inflammatory response Effects 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000003278 cryoglobulinemia Diseases 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000007475 hemolytic anemia Diseases 0.000 claims description 2
- 230000002949 hemolytic effect Effects 0.000 claims description 2
- 230000028996 humoral immune response Effects 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 208000000509 infertility Diseases 0.000 claims description 2
- 230000036512 infertility Effects 0.000 claims description 2
- 231100000535 infertility Toxicity 0.000 claims description 2
- 230000008595 infiltration Effects 0.000 claims description 2
- 238000001764 infiltration Methods 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000028709 inflammatory response Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 208000002574 reactive arthritis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 206010043207 temporal arteritis Diseases 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims 5
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 1
- 208000002740 Muscle Rigidity Diseases 0.000 claims 1
- 206010049816 Muscle tightness Diseases 0.000 claims 1
- 206010028424 Myasthenic syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000026062 Tissue disease Diseases 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023174060A JP2024020194A (ja) | 2017-12-01 | 2023-10-06 | 抗ｃｘｃｒ５抗体、その組成物及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593830P | 2017-12-01 | 2017-12-01 | |
| US62/593,830 | 2017-12-01 | ||
| US201862732985P | 2018-09-18 | 2018-09-18 | |
| US62/732,985 | 2018-09-18 | ||
| PCT/US2018/062829 WO2019108639A1 (en) | 2017-12-01 | 2018-11-28 | Anti-cxcr5 antibodies and compositions and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023174060A Division JP2024020194A (ja) | 2017-12-01 | 2023-10-06 | 抗ｃｘｃｒ５抗体、その組成物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021503888A JP2021503888A (ja) | 2021-02-15 |
| JP2021503888A5 true JP2021503888A5 (https=) | 2022-01-06 |
| JP7391839B2 JP7391839B2 (ja) | 2023-12-05 |
Family
ID=64734144
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526382A Active JP7391839B2 (ja) | 2017-12-01 | 2018-11-28 | 抗ｃｘｃｒ５抗体、その組成物及びその使用 |
| JP2023174060A Withdrawn JP2024020194A (ja) | 2017-12-01 | 2023-10-06 | 抗ｃｘｃｒ５抗体、その組成物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023174060A Withdrawn JP2024020194A (ja) | 2017-12-01 | 2023-10-06 | 抗ｃｘｃｒ５抗体、その組成物及びその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10875915B2 (https=) |
| EP (1) | EP3717516A1 (https=) |
| JP (2) | JP7391839B2 (https=) |
| KR (1) | KR102791781B1 (https=) |
| CN (1) | CN111615520A (https=) |
| AU (1) | AU2018375331B2 (https=) |
| BR (1) | BR112020010753A2 (https=) |
| CA (1) | CA3025536A1 (https=) |
| CO (1) | CO2020006453A2 (https=) |
| IL (1) | IL274809B1 (https=) |
| MX (2) | MX2020005662A (https=) |
| PE (1) | PE20210554A1 (https=) |
| PH (1) | PH12020550908A1 (https=) |
| SG (1) | SG11202003930YA (https=) |
| TW (1) | TWI830711B (https=) |
| WO (1) | WO2019108639A1 (https=) |
| ZA (1) | ZA202002760B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| MX2020005662A (es) | 2017-12-01 | 2020-08-20 | Pfizer | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos. |
| KR20260017503A (ko) * | 2020-02-14 | 2026-02-05 | 길리애드 사이언시즈, 인코포레이티드 | Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도 |
| WO2023010483A1 (en) * | 2021-08-05 | 2023-02-09 | Hifibio (Hk) Limited | Anti-human cxcr5 antibody and uses thereof |
| US10822379B1 (en) * | 2020-03-12 | 2020-11-03 | University of Pittsburgh—of the Commonwealth System of Higher Education | Molecules that bind to SARS-CoV-2 |
| TW202216771A (zh) * | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
| CN111995674B (zh) * | 2020-09-03 | 2022-02-11 | 中国人民解放军军事科学院军事医学研究院 | 抗COVID-19病毒中和抗体mhC3及其人源化抗体与应用 |
| CN112684185B (zh) * | 2020-12-25 | 2024-01-12 | 苏州旭光科星抗体生物科技有限公司 | 一种可溶性b7-h4定量检测试剂盒及其应用 |
| US20240101673A1 (en) | 2021-02-03 | 2024-03-28 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| US20240158517A1 (en) * | 2021-03-09 | 2024-05-16 | Hifibio (Hk) Limited | Anti-human cxcr5 antibody and uses thereof |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025262564A1 (en) | 2024-06-17 | 2025-12-26 | Pfizer Inc. | Use of anti-cxcr5 antibodies |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE37983T1 (de) | 1982-04-22 | 1988-11-15 | Ici Plc | Mittel mit verzoegerter freigabe. |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| WO1991006287A1 (en) | 1989-11-06 | 1991-05-16 | Enzytech, Inc. | Protein microspheres and methods of using them |
| WO1992019244A2 (en) | 1991-05-01 | 1992-11-12 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | A method for treating infectious respiratory diseases |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| EP0805678B1 (en) | 1995-01-05 | 2003-10-29 | THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN | Surface-modified nanoparticles and method of making and using same |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| EP0850051A2 (en) | 1995-08-31 | 1998-07-01 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| DK0885002T3 (da) | 1996-03-04 | 2011-08-22 | Penn State Res Found | Materialer og fremgangsmåder til forøgelse af cellulær internalisering |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| DE69732306T2 (de) | 1997-01-16 | 2006-01-12 | Massachusetts Institute Of Technology, Cambridge | Zubereitung von partikelhaltigen arzneimitteln zur inhalation |
| ATE296315T1 (de) | 1997-06-24 | 2005-06-15 | Genentech Inc | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| CA2336139C (en) | 1998-06-24 | 2008-10-14 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| ES2639222T5 (es) | 2000-10-06 | 2023-11-24 | Kyowa Kirin Co Ltd | Células que producen unas composiciones de anticuerpo |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| EP2180044A1 (en) | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| CA2467633C (en) | 2001-12-03 | 2012-03-27 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
| US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| JP4832719B2 (ja) | 2002-04-09 | 2011-12-07 | 協和発酵キリン株式会社 | ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬 |
| AU2003251471A1 (en) * | 2002-08-06 | 2004-02-25 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5) |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US8512701B2 (en) * | 2002-11-15 | 2013-08-20 | Morehouse School Of Medicine | Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| CN101014364B (zh) | 2002-12-24 | 2012-01-18 | 里纳特神经系统学公司 | 抗ngf抗体及其使用方法 |
| US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
| JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法 |
| PT1678314E (pt) | 2003-10-22 | 2012-11-27 | Keck Graduate Inst | Métodos de síntese de polipéptidos heteromultiméricos em levedura utilizando uma estratégia de conjugação haplóide |
| ES2672640T3 (es) | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| ES2538990T3 (es) | 2007-01-24 | 2015-06-25 | Kyowa Hakko Kirin Co., Ltd. | Composición de anticuerpo genéticamente recombinante que tiene una actividad efectora mejorada |
| US20080199481A1 (en) | 2007-02-21 | 2008-08-21 | Astrazeneca Ab | Compounds |
| CN111909273B (zh) * | 2007-08-29 | 2024-03-26 | 塞诺菲-安万特股份有限公司 | 人源化的抗-cxcr5抗体、其衍生物及它们的应用 |
| WO2010028795A1 (en) * | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Multivalent antibodies |
| WO2012010582A1 (en) * | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
| DK2608796T3 (en) | 2010-08-05 | 2019-03-18 | Seattle Genetics Inc | Inhibition of protein fucosylation in vivo using fucose analogues |
| AU2011295902B2 (en) | 2010-09-02 | 2014-12-04 | Vaccinex, Inc. | Anti-CXCL13 antibodies and methods of using the same |
| JP6522585B2 (ja) * | 2013-05-02 | 2019-05-29 | アレス トレーディング ソシエテ アノニム | Ｃｘｃｒ５に対するモノクローナル抗体 |
| JP6343011B2 (ja) | 2013-10-07 | 2018-06-13 | プレステージ バイオファーマ プライベート リミテッド | 抗体発現用バイシストロニック発現ベクター及びそれを用いた抗体の生産方法 |
| AU2015305850A1 (en) | 2014-08-22 | 2017-04-06 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind CXCR5 |
| US10647756B2 (en) | 2015-05-18 | 2020-05-12 | Pfizer Inc. | Humanized antibodies |
| MX2020005662A (es) | 2017-12-01 | 2020-08-20 | Pfizer | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos. |
-
2018
- 2018-11-28 MX MX2020005662A patent/MX2020005662A/es unknown
- 2018-11-28 EP EP18821813.5A patent/EP3717516A1/en active Pending
- 2018-11-28 US US16/202,749 patent/US10875915B2/en active Active
- 2018-11-28 CN CN201880077727.6A patent/CN111615520A/zh active Pending
- 2018-11-28 JP JP2020526382A patent/JP7391839B2/ja active Active
- 2018-11-28 TW TW107142392A patent/TWI830711B/zh active
- 2018-11-28 AU AU2018375331A patent/AU2018375331B2/en active Active
- 2018-11-28 KR KR1020207015164A patent/KR102791781B1/ko active Active
- 2018-11-28 PE PE2020000645A patent/PE20210554A1/es unknown
- 2018-11-28 CA CA3025536A patent/CA3025536A1/en active Pending
- 2018-11-28 BR BR112020010753-0A patent/BR112020010753A2/pt unknown
- 2018-11-28 SG SG11202003930YA patent/SG11202003930YA/en unknown
- 2018-11-28 WO PCT/US2018/062829 patent/WO2019108639A1/en not_active Ceased
-
2020
- 2020-05-14 ZA ZA2020/02760A patent/ZA202002760B/en unknown
- 2020-05-20 IL IL274809A patent/IL274809B1/en unknown
- 2020-05-27 CO CONC2020/0006453A patent/CO2020006453A2/es unknown
- 2020-05-29 PH PH12020550908A patent/PH12020550908A1/en unknown
- 2020-07-13 MX MX2022015258A patent/MX2022015258A/es unknown
- 2020-11-20 US US17/100,245 patent/US11958901B2/en active Active
-
2023
- 2023-10-06 JP JP2023174060A patent/JP2024020194A/ja not_active Withdrawn
-
2024
- 2024-03-04 US US18/594,234 patent/US20240279326A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021503888A5 (https=) | ||
| Bernstein et al. | Engineering the IL‐4/IL‐13 axis for targeted immune modulation | |
| US10358490B2 (en) | Methods of treating inflammation with IL-17A/F and IL-23P19 bispecific antibodies | |
| EP3390444B1 (en) | Anti-tl1a antigen binding proteins and uses thereof | |
| IL274809B1 (en) | Antibodies against CXCR5 and compositions and uses thereof | |
| TWI489996B (zh) | Ｃｄ１２７結合蛋白質 | |
| CA2705292C (en) | Humanized antibodies against tl1a | |
| KR101340699B1 (ko) | 인간 모노클로날 항체 인간 ｃｄ１３４（ｏｘ４０） 및이의 제조 및 사용 방법 | |
| TWI646105B (zh) | Ｉｌ－２１抗體 | |
| CN106554417A (zh) | 抗ox40抗体和使用其的方法 | |
| JP2024056047A (ja) | Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション | |
| JP2009544761A (ja) | 低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法 | |
| CA3064518A1 (en) | Btla agonist antibodies and uses thereof | |
| JP2016524595A (ja) | Ｃｘｃｒ５に対するモノクローナル抗体 | |
| Tanaka et al. | Interleukin-6; pathogenesis and treatment of autoimmune inflammatory diseases | |
| WO2014139425A1 (zh) | 一种抗Blys的单克隆抗体及含有该抗体的药物组合物 | |
| JP2025124594A (ja) | 抗ｉｌ２７ｒ抗体およびその使用の方法 | |
| JP2025525829A (ja) | 抗ｉｌ２７ｒ抗体およびその使用の方法 | |
| HK40052031A (en) | Bispecific antibody and use thereof | |
| BR122025021892A2 (pt) | Células hospedeiras | |
| HK1171664A (en) | Humanized antibodies against human il-22ra |